Biomea Fusion, Inc.
BMEA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840439
No open-market purchases or sales by Biomea Fusion, Inc. insiders were filed in the last 90 days; 61 institutions reported holding it in 13F filings for Q2 2026, worth $36.8M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Biomea Fusion, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Biomea Fusion, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Aguiar Eric | Director | – | Jun 12, 2026 | 1 |
| Faust Elizabeth | Director | – | Jun 12, 2026 | 1 |
| Ray Sumita | Director | – | Jun 12, 2026 | 1 |
| Averill Julianne | Director | – | Jun 12, 2026 | 1 |
| Erdtmann Rainer M | See Remarks | 723,027 | Apr 3, 2026 | 3 |
| Hitchcock Michael J.M. | Interim CEO | 115,000 | Apr 3, 2026 | 2 |
| Cormorant Asset Management, LP | Other: Former 10% Holder | 3,570,872Indirect | Aug 1, 2025 | 0 |
| Chen Bihua | Other: Former Director | 3,570,872Indirect | Aug 1, 2025 | 0 |
| Cormorant Global Healthcare Master Fund, LP | Other: Former 10% Holder | 3,570,872Indirect | Aug 1, 2025 | 0 |
| Cormorant Private Healthcare Fund III LP | Other: Former 10% Holder | 3,570,872Indirect | Aug 1, 2025 | 0 |
| Valle Franco | Chief Financial Officer | 42,995 | Dec 2, 2024 | 0 |
| Frias Juan Pablo | Chief Medical Officer | 349 | Jun 12, 2024 | 0 |
| Butler Thomas Andrew | Chief Executive Officer | 228,470Indirect | Jan 18, 2024 | 0 |
| A2A Pharmaceuticals, Inc. | 10% Owner | 3,500,000 | Jun 2, 2023 | 0 |
| Biomea Health, LLC | 10% Owner | 0Indirect | Jun 3, 2022 | 0 |
| Stergiopoulos Sotirios | Director | 4,400,000Indirect | Sep 21, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 15, 2025 (view filing) | Dec 11 | 4 days | Erdtmann Rainer MSee Remarks | PPurchase | +30.0K | $1.43 | +$42.9K | +4.3%723.0K after | |
| Dec 4, 2025 (view filing) | Dec 2 | 2 days | Hitchcock Michael J.M.Interim CEO | PPurchase | +100.0K | $0.99 | +$99.0K | +666.7%115.0K after | |
| Dec 2, 2025 (view filing) | Nov 28-Dec 1 | 4 days | Erdtmann Rainer MSee Remarks | PPurchase | +50.0K | $1.09 | +$54.5K | +7.8%693.0K after | 2 lots |
| Oct 1, 2024 (view filing) | Sep 30 | 1 day | Hitchcock Michael J.M.Director | PPurchase | +10.0K | $10.06 | +$100.6K | +200.0%15.0K after | |
| Jun 12, 2024 (view filing) | Jun 11 | 1 day | Valle FrancoChief Financial Officer | PPurchase | +12.5K | $4.43 | +$55.4K | +41.7%42.5K after | |
| Jun 2, 2023 (view filing) | May 31-Jun 1 | 2 days | A2A Pharmaceuticals, Inc.10% Owner | SSale | −125.0K | $34.11 | −$4.26M | −3.4%3.50M after | 2 lots |
| May 17, 2023 (view filing) | May 12 | 5 daysLate | A2A Pharmaceuticals, Inc.10% Owner | SSale | −25.0K | $33.84 | −$846.0K | −0.7%3.63M after | |
| May 10, 2023 (view filing) | May 8-9 | 2 days | A2A Pharmaceuticals, Inc.10% Owner | SSale | −250.0K | $34.30 | −$8.57M | −6.4%3.65M after | 2 lots |
| Apr 26, 2023 (view filing) | Apr 20 | 6 daysLate | A2A Pharmaceuticals, Inc.10% Owner | SSale | −200.0K | $29.12 | −$5.82M | −4.9%3.90M after | |
| Apr 6, 2023 (view filing) | Mar 31 | 6 days | A2A Pharmaceuticals, Inc.10% Owner | SSale | −200.0K | $31.25 | −$6.25M | −4.7%4.10M after | Amended |
| Apr 3, 2023 (view filing)4:30 PM ET | Mar 30 | 4 days | Chen Bihua and 3 othersDirector, 10% Owner | PPurchase | +400.0K | $30.00 | +$12.0M | +12.6%3.57M after | |
| Feb 10, 2023 (view filing) | Apr 15, 2021 | 666 days | Erdtmann Rainer MPresident and COO | PPurchase | +8.40K | $17.00 | +$142.8K | New position3.00K after | Amended3 lots |
| Nov 16, 2022 (view filing) | Nov 14 | 2 days | Hitchcock Michael J.M.Director | PPurchase | +5.00K | $7.93 | +$39.6K | New position5.00K after | |
| Nov 14, 2022 (view filing) | Nov 11 | 3 days | Valle FrancoChief Financial Officer | PPurchase | +4.10K | $7.63 | +$31.3K | +30.8%17.4K after | |
| Aug 19, 2022 (view filing) | Aug 16 | 3 daysLate | A2A Pharmaceuticals, Inc.10% Owner | PPurchase | −30.7K | $13.87 | −$425.6K | −0.7%4.30M after | |
| Jul 25, 2022 (view filing) | Jul 21 | 4 days | A2A Pharmaceuticals, Inc.10% Owner | SSale | −34.7K | $11.21 | −$388.5K | −0.8%4.33M after | |
| Jun 28, 2022 (view filing) | Jun 24 | 4 days | A2A Pharmaceuticals, Inc.10% Owner | SSale | −34.7K | $11.76 | −$407.6K | −0.8%4.37M after | |
| Jan 18, 2022 (view filing) | Jan 14 | 4 days | Valle FrancoChief Financial Officer | PPurchase | +10.0K | $8.68 | +$86.8K | New position10.0K after | |
| Sep 21, 2021 (view filing) | Sep 17 | 4 days | A2A Pharmaceuticals, Inc.10% Owner | PPurchase | +34.7K | $10.96 | +$379.9K | +0.8%4.40M after | Duplicate filing |
| Sep 21, 2021 (view filing) | Sep 17 | 4 days | Stergiopoulos SotiriosDirector | PPurchase | +34.7K | $10.96 | +$379.9K | +0.8%4.40M after | |
| Aug 25, 2021 (view filing) | Aug 23 | 2 days | Erdtmann Rainer MPresident & COO | PPurchase | +24.0K | $13.20 | +$316.8K | +11.7%228.5K after | Duplicate filing |
| Aug 25, 2021 (view filing) | Aug 23 | 2 days | Butler Thomas AndrewCEO | PPurchase | +24.0K | $13.20 | +$316.8K | +11.7%228.5K after | |
| Aug 19, 2021 (view filing) | Apr 15-Aug 18 | 126 daysLate | Butler Thomas AndrewCEO | PPurchase | +204.5K | $16.15 | +$3.30M | New position204.5K after | 3 lots |